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ABSTRACT
Bone loss is a well-documented change during and after long-duration spaceflight. Many types of countermeasures to bone loss have
been proposed, includingvitamin Ksupplementation. Theobjective ofthis series of studieswasto measurechangeinvitamin Kstatus in
response to microgravity under a variety of spaceflight and spaceflight analog (model) conditions, including long-duration spaceflight
studies (n¼15), three bed rest studies (n¼15, 49, and 24), and a 14-day saturation dive (n¼6). In crew members who flew 2–6 months
on the International Space Station, in-flight and postflight plasma phylloquinone concentrations were unchanged from the preflight
mean. Consistent with this finding, urinary g-carboxyglutamic acid (GLA), a measure of vitamin K-dependent protein turnover, did not
change in response to flight. Serum undercarboxylated osteocalcin (%ucOC), a measure of vitamin K function, was generally unchanged
in response to flight. Spaceflight findings were corroborated by findings of no changes in phylloquinone, urinary GLA, or %ucOC during
or after bed rest in three separate bed rest studies (21–90 days in duration) or after a 14-day saturation dive. The data presented here do
not support either a need for vitamin K supplementation during spaceflight or the suggestion of using vitamin K as a bone loss
countermeasure in spaceflight.  2011 American Society for Bone and Mineral Research.
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Introduction
B
onelossisaseeminglyinevitableoutcomeofspaceflight.
(1–4)
Of the many types of bone loss countermeasures evaluated
to date, none have been proven effective during flight.
(5) Vitamin
K is a nutrient linked to bone health and as such has been
suggested as a potential countermeasure. Regardless of its
efficacy in preventing bone loss, if the vitamin K status of
astronauts were established as suboptimal during spaceflight,
vitamin K supplementation might be warranted.
Vitamin K is an enzyme cofactor for the production of g-
carboxyglutamic acid (GLA) residues in specific proteins (GLA
proteins). GLA proteins are involved in a number of regulatory
functions, including bone mineralization. When vitamin K status
is suboptimal, the assumption is that GLA proteins are not fully
carboxylated and will thus be less effective. Osteocalcin is a GLA
protein that is synthesized by osteoblasts and is thought to have
a role in regulation of bone mineralization. Undercarboxylated
osteocalcin (ucOC) provides a good measure of vitamin K
functional status, with specific regard to bone.
(6)
Vitamin K has been included as a concern for the nutritional
status of astronauts because of uncertainty about the efficiency
ofvitaminKsynthesisbythegastrointestinalflorainmicrogravity
and about potentially altered absorption in this unique
environment.
(5) A known and consistent occurrence in the
spaceflight environment is loss of bone mineral. Data showing a
role for vitamin K status and/or vitamin K supplementation in
bone health on Earth has led some to suggest that vitamin K
treatment could play a role in protecting bone against
microgravity-induced mineral loss.
(7,8)
Three studies provide evidence that vitamin K status of
astronauts may be suboptimal during spaceflight and suggest
that vitamin K supplementation may be warranted. Carboxyla-
tion of osteocalcin was decreased in two cosmonauts during
both short- and long-duration spaceflight, and it returned to
preflight levels soon after landing.
(9) In a case study with in-flight
vitamin K supplementation, a ‘‘pharmacological dose’’ of 10mg
vitamin K1/day decreased undercarboxylated osteocalcin to
preflight levels.
(9,10) Concomitant with the positive changes in
vitamin K status with supplementation, urinary calcium tended
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948to decrease, although as the authors state, inferring a causal
relation between the increased vitamin K status and the
decreased urinary calcium from these data alone is highly
speculative.
(10)
Finally, a third observational study of plasma phylloquinone in
11 astronauts before and after 4–6 months of spaceflight on the
International Space Station (ISS) reported an approximate 40%
decrease in plasma phylloquinone after flight, with no change in
urinary GLA excretion.
(11) The estimated menu content of
vitamin K in the foods provided to astronauts aboard the ISS is
105 19mg/day,
(5) which is more than the documented ISS
requirement (80mg/day)
(12) but approximates the median usual
intake of 120mg/day for adult males based on the Third National
Health and Nutrition Examination Survey (NHANES III; 1988–
1994).
(13)
It is not known whether the apparent changes in vitamin K
status after flight result from an effect of microgravity on vitamin
K metabolism or simply from a change in dietary intake during
flight. If the change in vitamin K status is a decrease with clinical
relevance, then we would expect concurrent changes in the
functionalbiomarkersofvitamin Kstatus aswell.Inthis paperwe
present data showing the effect of microgravity on markers of
vitamin K status in astronauts before, during, and after long-
duration flights on the International Space Station, as well as the
effects of several ground analogs of spaceflight, including bed
rest and saturation diving, where dietary intake was carefully
monitored.
Methods
Although the basic results (general nutritional results and results
from other experiment teams, including bone, muscle, and
cardiovascular physiology) from the bed rest studies reported
here have been previously published, this is the first report of
vitaminKstatusinthesestudies.Detailsandcitationsfromearlier
studies are included below.
As stated in the original publications, all protocols described
below were reviewed and approved by the NASA Johnson Space
Center Committee for the Protection of Human Subjects (and
often by other local institutional review boards), and written
informed consent was obtained from all subjects. The analysis of
vitaminKinthesestudieswasalsoapprovedbytheTuftsMedical
Center Institutional Review Board.
Spaceflight
Subjects (n¼15, 11 male and 4 female) were astronauts on
International Space Station Expeditions 14–22 (missions of 48–
215 days duration, flown between 2003 and 2010). Blood and
two consecutive 24-hour urine samples were collected approxi-
mately 180 and 45 days before launch and again on landing day
(return, or Rþ0 days). Phylloquinone and urinary GLA data from
the first 11 US International Space Station crew members
(Expeditions 1–8) have been published.
(11) In addition to the
nominal pre- and postflight collections, these crew members
provided five blood and 24-hour urine collections during
spaceflight at about flight day 15 (designated FD15), FD30,
FD60, FD120, and FD180. Given that flight durations varied, not
allcrewshadfivein-flightsessions.Bloodsampleswerecollected
using standard phlebotomy techniques. For in-flight blood
collections, samples were collected into evacuated serum or
plasma gel separator tubes. The tubes were centrifuged at 3800
RPM (1500 g) for 30min and then placed in a  808C freezer on
the International Space Station (with a typical temperature of
 968C). The samples were returned to Earth within 6 to
12 months in a specially designed cold bag that was capable of
maintainingatleast 308Corloweruntillandingorinapowered
 968C freezer on the Space Shuttle. Within hours of landing,
samples were transferred to dry ice for transport to Houston,
where they were stored in a  808C freezer until analysis. Except
for samples collected on Rþ0 (landing day), all blood samples
were collected after an 8-hour fast. Urine collected before and
after flight was collected into single-void urine containers (Cole-
Parmer, Niles, IL, USA). Samples were stored with ice packs or
refrigerated until they were processed, within 24hours of
collection. A pooled 24-hour aliquot was prepared for GLA
analysis and stored frozen at  808C until analysis. In-flight urine
voids were collected into urine collection devices containing
1mL of a LiCl solution as a volume marker. After being voided
into the device, the sample was thoroughly mixed, and a syringe
aliquot was obtained and then frozen until return to Earth about
6–12months later.Afterlanding,the in-flighturine sampleswere
analyzed for lithium concentration to determine void volume
and subsequently to prepare 24-hour pools, as previously
described.
(3,14)
Bed rest
Vitamin K status of subjects in three different bed rest studies
was determined. The first study was a 21-day head-down-tilt
(HDT) bed rest with or without an artificial gravity (AG)
countermeasure, performed at the General Clinical Research
Center (GCRC) at the University of Texas Medical Branch (UTMB)
in Galveston, TX, USA. The details of the AG protocol are
describedinotherarticles.
(15,16) Briefly, duringthe bedrestphase
of the study, all 15 subjects (8 AG and 7 controls, all male) were
confined to 68 HDT bed rest. AG subjects were exposed to short-
radius centrifuge loading for 60min each day during bed rest to
achieve z-axis loading of 2.5 G at the feet and about 1.0 G at the
heart. Blood samples and 24-hour urine pools were collected for
vitamin K–related analyses twice before, three times during, and
twice after bed rest. Diets were controlled and were matched for
all subjects by relative study day.
The second bed rest study reported here is from a series of 60-
to 90-day bed rest studies with (n¼18, 12 male and 6 female) or
without (n¼31, 21 male and 10 female) a vibration counter-
measure on a vibration plate placed at the feet during bed rest.
The details of the vibration protocol are described elsewhere.
(17)
The studies were performed at the UTMB GCRC, and diets were
controlled and matched for all subjects. Details about the food
system used for the 21-day and 60- to 90-day bed rest studies at
UTMB have been published.
(18,19)
A third study was a 60-day 68 HDT bed rest study with or
without an exercise or nutrition countermeasure, conducted at
the Institute for Space Medicine and Physiology (MEDES) in
Toulouse, France. All of the subjects in this study, dubbed the
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study, were female. Details about the study protocol have been
published.
(20) Briefly, the control group (n¼8) did not exercise,
nor were they provided a nutritional countermeasure during bed
rest. The exercise group (n¼8) performed aerobic and resistive
exercise during bed rest and the nutrition group (n¼8) was
given an amino acid nutritional supplement during bed rest.
Blood samples and 24-hour urine sample pools were collected
twice before, three times during, and once after bed rest.
NEEMO
Another ground analog of spaceflight in which we determined
vitamin K status was the NASA Extreme Environment Mission
Operations (NEEMO) V project, which was a 14-day saturation
dive with crew members (n¼6, 2 female, 4 male) living ina small
habitat about 60m below the ocean surface, about 4km (2.5mi)
off the coast of Key Largo, FL.
(21) In this study, blood and 24-hour
urine samples were collected twice before, twice during, and
twice after the dive. Foods consumed during the mission were
flight-like foods, and the quantities consumed were recorded
and analyzed for nutrient content.
(21)
Biochemical analyses
Undercarboxylated osteocalcin from all studies presented was
measured in serum using an established method
(6) and a
commercially available RIA kit (Biomedical Technologies,
Stoughton, MA, USA). The assay uses a polyclonal antibody for
intact human osteocalcin and recognizes both intact osteocalcin
and the large N-terminal midmolecule fragment.
(6) Under-
carboxylated osteocalcin analyses for all studies reported, except
spaceflight, were run by Dr. Booth’s laboratory; analyses for the
spaceflight study were run at the Johnson Space Center in
Houston, TX.
In blood samples from all subjects in the artificial gravity bed
rest study, the 60-day bed rest study in France, and the NEEMO V
study, and from 18 subjects in the 60- to 90-day bed rest study at
UTMB, plasma phylloquinone was measured at Tufts University
using a liquid-chromatographic method with fluorometric
detection.
(22) In all samples from the 15 crew members with
pre-, in-, and postflight data and in samples from 31 subjects in
the 60- to 90-day bed rest studies, plasma phylloquinone was
measuredintheNutritionalBiochemistryLaboratoryattheNASA
Johnson Space Center (JSC) using the microelution solid-phase
extraction/HPLC method described below. Both labs participate
in the vitamin K external quality assurance scheme (KEQAS) that
monitors and reports the accuracy of phylloquinone measure-
ments.KEQASsamplesfrom lots41,42,and43 weremeasuredin
both labs and the coefficient of variation was determined to be
13 5%.
Urinary GLA from the artificial gravity bed rest study, the 60-
day bed rest study in France, the NEEMO V study, and some of
the spaceflights was determined by reversed-phase HPLC with
fluorometric detection
(23) at Tufts University. The remaining GLA
samples from spaceflight and the 60- to 90-day bed rest study
were quantified using a precolumn derivatization with ortho-
phthaldialdehyde and a silica-based anion-exchange HPLC
column
(11) in the Nutritional Biochemistry Laboratory at JSC.
Plasma phylloquinone was measured at JSC using microelu-
tion solid-phase extraction. Separation was performed using an
Agilent(SantaClara,CA,USA)1100HPLCsystemequippedwitha
Thermo Scientific (West Palm Beach, FL, USA) Hypersil-100 C18
column (4.6 150mm, 5mm particle size), using postcolumn
reduction and fluorescence detection with the excitation
wavelength at 244nm and emission at 430nm. The mobile
phase contained, per liter, 994.5mL methanol and 5.5mL of an
aqueous solution of 2mol/L zinc chloride, 1mol/L acetic acid,
and1mol/Lsodiumacetate.Anisocraticmodewithaflowrateof
1.5mL/min was used in the assay. The column temperature was
maintained at 308C during analysis. Plasma samples were
precipitated by 1:4 (v/v) dilution with ethanol after adding 20mL
of 1:19 (v/v) ethanol-diluted internal standard (a proprietary
vitamin derivative that is a component of a commercial assay kit
for vitamin K1 assays, ALPCO Diagnostics, Salem, NH, USA) and
then centrifuged at 13,500 RPM (18,779 g)a t4 8C for 5min. The
Waters Oasis HLB 96-well microelution solid-phase extraction
plate (Waters Corp., Milford, MA, USA) was equilibrated with
0.25mL methanol followed by 0.25mL deionized water. Then
0.1mLdeionizedwater wasaddedtotheplasmaprecipitate, and
the supernatant of the sample was transferred to the
microextraction plate. The plate was washed with 0.25mL
50% methanol in deionized water and then eluted with 75mLo f
1:1isopropanol:acetonitrile(v/v)intoaWaters0.8-mLroundwell,
96-well collection plate (Waters Corp.). The sample was
transferred to a 400-mL flat-bottom glass insert (Alltech,
Deerfield, IL, USA) in a 1.5-mL amber vial and capped; 60mL
was used for HPLC analysis.
Statistical analyses
A repeated-measures one-way ANOVA was performed on
spaceflight data and NEEMO data. A repeated-measures two-
way ANOVA was performed on the bed rest studies, with time
and countermeasure (exercise and artificial gravity) as variables.
Each bed rest study was analyzed separately. A separate
repeated-measures two-way ANOVA was performed to deter-
mine whether the lab where analyses were performed had an
effect on vitamin K values. If overall significant differences were
detected, apost hocBonferroni t-test wasperformed toestablish
differences between time points or within treatments. Statistical
analyses were performed using Sigma Stat 3.11 (Systat Software,
San Jose, CA, USA).
Results
Spaceflight
The phylloquinone data from the 15 subjects with pre-, in-, and
postflight data are presented in Table 1. There was one outlier at
FD60 (the value was 13.2nmol/liter). Only when the outlier was
removed, the phylloquinone concentration at FD15 was
significantly less than the preflight mean, but the preflight
mean was not different from the other time points.
The postflight (Rþ0) mean of urinary GLA was not different
from the preflight mean, nor was there a difference during flight
(Table 1).
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FD15 and Rþ0, but these changes were small, and likely reflect
the narrow range of the preflight data (Table 1). Although a
dramatic increase seemed to occur at FD180, this happened
largelybecausethe numberofsubjects onflights ofthisduration
(and thus with data available at this time point) was very small.
Unfortunately, dietary phylloquinone intake data were not
available from the flight studies at any time before, during, or
after flight.
Bed rest
Average consumption of vitamin K before, during, and after bed
rest for the AG group in the 21-day bed rest study was 174 39
(mean SD), 138 29, and 172 38mg/day and for the control
group was 207 14, 161 15, and 202 15mg/day, respec-
tively. The mean vitamin K intake before, during, and after bed
rest for the controls in the 60- to 90-day bed rest studies was
137 26, 120 24, and 134 25mg/day, respectively. For the
subjects with the vibration countermeasure, vitamin K intake
before, during, and after bed rest was 158 26, 128 17, and
131 24mg/day, respectively. Dietaryphylloquinone intake data
were not available from the 60-day study conducted in France.
No significant differences in plasma phylloquinone concen-
tration were found during or after 21 days of bed rest with or
withoutartificial gravity (Table2),nor wasthere adifference after
60 days of bed rest with or without exercise or a nutritional
countermeasure (Table 3). With or without a vibration counter-
measure, plasma phylloquinone concentration decreased 35–
38% in 8 days after reambulation from 60–90 days of bed rest
(p<.01, Table 4). There was no significant difference between
analyses performed at the Johnson Space Center and those
performed at Tufts. Urinary GLA was significantly affected by
time during the 21-day (Table 2) and 60- to 90-day (Table 4) bed
rest studies, where a significant main effect occurred, but there
were no differences between time points when the post hoc test
wasperformed. Undercarboxylated osteocalcin wasnotdifferent
during bed rest in any of the bed rest studies, but in the vibration
group in the 60- to 90-day bed rest studies, it was lower overall
than in controls (Table 4, p<.01).
NEEMO
When crew members on a 14-day saturation dive consumed
spaceflight-like foods containing a per-subject total of
23 14mg vitamin K/day during the dive, neither plasma
Table 1. Markers of Vitamin K Status Before, During, and After Long-Duration Spaceflight on ISS
Preflight FD15 FD30 FD60 FD120 FD180 Rþ0R þ30
Phylloquinone (nmol/L) 1.4 0.7 0.4 0.3 1.3 1.2 1.7 3.2 0.7 0.3 0.7 0.5 1.0 0.6 0.9 0.8
n 15 15 15 15 12 9 15 15
GLA (mmol/day) 38 74 1  14 40 94 0  94 0  10 46 12 40 74 5  9
n 15 15 15 15 12 9 15 15
ucOC (%) 37 74 3  6
  39 44 0  54 1  54 1  74 2  6
  35 5
n 14 13 12 14 11 8 15 15
Data are means SD. FD, flight day; Rþ0, returnþ0 days (landing day); GLA, g-carboxyglutamic acid; ucOC, undercarboxylated osteocalcin.
Phylloquinone was measured in plasma, GLA in urine, and ucOC in serum. The data reported above include all available data. There was one outlier
in the phylloquinone data at FD60 (value was 13.2nmol/L); when the outlier was removed, the remaining data were 0.9 0.7, and there was a significant
decrease in phylloquinone at FD15 (p<.01). The data were analyzed using a repeated-measures one-way ANOVA, and there were no significant
differences when the one outlier was not removed.
 p<.001, significantly different from preflight.
Table 2. Vitamin K Status Before, During, and After 21 Days of Head-Down-Tilt Bed Rest in Men With or Without an Artificial Gravity
Countermeasure
Pre-BR BR8 BR15 BR21 Rþ0/1 Rþ8 n
Phylloquinone (nmol/L)
AG 2.2 0.9 1.9 0.8 1.8 0.7 1.7 0.6 N/A 1.9 0.8 8
Control 2.7 0.9 3.1 0.9 2.8 1.2 2.8 1.2 N/A 2.3 1.1 7
GLA
a (mmol/day)
AG 47 13 48 14 45 14 46 12 43 14 48 14 8
Control 50 14 49 11 50 11 48 10 47 11 51 11 7
ucOC (%)
AG 46 18 43 23 34 15 39 26 N/A 27 16 8
Control 39 14 34 16 42 14 32 11 N/A 39 77
Dataaremeans SD. BR8,bed restday 8; Rþ0/1,recoveryþ0 or 1 dayafter reambulation; AG, artificialgravity countermeasure (centrifugation while in
head-down-tilt position to achieve z-axis loading of 2.5 G at the feet and 1.0 G at the heart for 1h per day for 21 days). N/A, data not available; GLA, g-
carboxyglutamic acid; ucOC, undercarboxylated osteocalcin. Phylloquinone was measured in plasma, GLA in urine, and ucOC in serum. Data were
analyzed using a repeated-measures two-way ANOVA.
aSignificant effect of time, p<.05 (no differences between time points with a post hoc Bonferroni t-test).
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course of the mission (Table 5).
Discussion
The limited spaceflight data available related to vitamin K led
investigators to propose that vitamin K status was altered during
long-duration spaceflight. Data from the first 11 US crew
members aboard the International Space Station (4–6 months of
spaceflight) showed a 42% decrease in plasma phylloquinone
concentration after spaceflight.
(11) Two cosmonauts on the
Russian space station Mir had a rapid increase in under-
carboxylated osteocalcin that remained high during a 21-day
and a 180-day spaceflight.
(9) One of those two cosmonauts was
also the subject in a case study in which the cosmonaut’s
carboxylated osteocalcin increased after vitamin K supplemen-
tation during the 180-day flight.
(9,10) Taken together, these lines
of evidence suggest that vitamin K status is lower during flight.
However, as reported here, in plasma samples from 15 crew
members who have flown on the ISS since 2006, we found no
change in plasma phylloquinone concentration during or after
flight compared to the mean preflight concentration. More
importantly, however, for the first time we have analyzed plasma
phylloquinone, serum undercarboxylated osteocalcin, and
urinary GLA during flight, and the data presented here do not
support the idea that a decrease in vitamin K status is induced by
microgravity.
Plasma phylloquinone decreased early during flight, but after
180 days of spaceflight its concentration was not different from
preflight concentrations (Table 1). Because we observed a
decrease in vitamin K status in our previous study,
(11) we would
have expected to see an increase in undercarboxylated
osteocalcin and decrease in urinary GLA, and neither was
observed during or after long-duration spaceflight. Fluid shifts
mightaccount forsomeofthis(throughincreasedplasmavolume
and dilution of phylloquinone), but a general decrease in plasma
constituents was not observed after flight (although this may be
related to tighter control over other constituents). Another
explanation is related to phylloquinone intake. It is well
documented that plasma phylloquinone concentrations fluctuate
within 24hours in response to changes in dietary phylloquinone
intakes.
(23–25) Dietary intake in general was likely lower in the last
24hours of flight, and this could explain the decreased plasma
phylloquinone on landing day in our previous study.
(11) Without a
concomitantdeclineinvitaminKstatusasmeasuredbyfunctional
biomarkers, the transient decrease in phylloquinone on landing
day is likely not clinically relevant. Furthermore, in samples
collected 30 days after landing, when fluid balance would have
largely returned toward normal, patterns observed in the data
were similar to those on landing day.
Aside from any association with spaceflight, a low vitamin K
status is often associated with lower bone mass in observational
studies.
(26) However, the preponderance of randomized clinical
trials in men and women suggest that phylloquinone supple-
mentation has no impact on age-related bone loss under
conditions of normal gravity (that is, on the ground).
(27) One
suggestion for the discrepancy between the findings of
observational studies and the clinical trials is that vitamin K
Table 3. Vitamin K Status Before, During, and After a 60-Day
Head-Down-Tilt Bed Rest in Women With or Without an Exercise
or Nutrition Countermeasure
Pre-BR BR15 BR30 BR59 Post-BR
Phylloquinone (nmol/L)
Exercise 1.0 0.4 N/A 1.7 0.8 1.5 0.7 1.3 0.7
Control 1.1 0.6 N/A 1.3 0.6 1.2 0.7 0.9 0.4
Nutrition 1.3 0.6 N/A 0.9 0.2 1.0 0.3 1.0 0.5
GLA (mmol/day)
Exercise 39 84 0  63 8  63 5  19 42 18
Control 36 73 4  83 5  11 34 63 8  9
Nutrition 35 33 6  33 7  63 5  53 4  5
ucOC (%)
Exercise 39 10 N/A 41 74 3  17 45 20
Control 33 15 N/A 41 13 41 13 42 7
Nutrition 43 7 N/A 44 94 2  15 40 15
n 8 8 888
Data are means SD. BR, bed rest; post-BR, blood or urine collected
between 5 and 7 days after reambulation; GLA, g-carboxyglutamic acid;
N/A, data not available; ucOC, undercarboxylated osteocalcin. The data
wereanalyzedbyrepeated-measurestwo-wayANOVAandtherewereno
significant differences.
Table 4. VitaminKStatusBefore,During,andAfter60–90DaysofHead-Down-TiltBedRestWithorWithoutaVibrationCountermeasure
Pre-BR BR30 BR60 BR90 Rþ8 n
Phylloquinone
a (nmol/L)
Control 1.7 1.0 1.4 1.3
  1.5 1.4 1.5 1.2 1.1 0.8
  31
Vibration 2.1 1.4 1.5 0.9 2.0 1.3 1.7 1.0 1.3 0.6
  18
GLA (mmol/day)
Control 40 94 1  10 36 11 41 84 2  13 31
Vibration 41 11 41 10 43 12 42 11 42 13 18
ucOC (%)
Control 48 17 46 21 56 13 50 14 52 17 31
Vibration
b 26 21 40 26 40 33 32 21 38 31 18
Data are means SD. BR, bed rest; Rþ8, 8 days after reambulation from bed rest; GLA, g-carboxyglutamic acid; ucOC, undercarboxylated osteocalcin.
aSignificant effect of time, p<.01;
bsignificant group effect, p<.01.
 Significantly different from pre-BR as determined by a post hoc Bonferroni t-test.
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bone loss.
(28,29) This inconclusiveness of the ground-based data
on phylloquinone supplementation for bone protection further
supports the idea that supplementation during spaceflight for
mitigation of bone loss is not warranted at this time. The vitamin
K supplementation case study was conducted on the Russian
space station Mir in 1995, and the food system was composed
entirely of Russian foods. On the ISS, and on Mir flights when US
crew members were aboard, the food system was about half
American space food and half Russian space food. Whether this
difference affected vitamin K intakes is impossible to know, but
the supplement administered in the Russian space study
contained 10mg/day, which, given its high dose, would have
superseded any dietary effects on measures of vitamin K status.
Although the initial goals and hypotheses of the bed rest
studies presented here did not include the study of vitamin K
status in particular, we presented the data here as evidence
supporting the spaceflight data. Bed rest is a well-accepted
model for certain aspects of spaceflight.
(18,30,31) No striking changes
occurred in phylloquinone, urinary GLA, or undercarboxylated
osteocalcin during bed rest in any of the studies, nor was vitamin
K status affected by any of several countermeasures.
The data presented here, though largely negative, are
important nonetheless. This is the first complete picture of a
vitamin K status assessment during spaceflight with supporting
data from ground-based models of spaceflight. The data
presented here do not support vitamin K supplementation as
a countermeasure during spaceflight to prevent a vitamin K
deficiency (or mitigate bone loss), because there was no
evidence for a decrease in vitamin K status during flight.
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